Intellectual Property

Intellectual Property

The development work at Cyxone and the research performed by collaborating scientists continues to generate new patent opportunities for the company, and we regularly assess those opportunities.

In order to increase the commercial potential for rabeximod and its attractiveness to potential partners, we have taken measures to expand its market exclusivity period. A number of additional patent applications have recently been filed, and we will continue exploring more options to further expand and strengthen our IP platform.


Patent nameGeographiesStatusExpiration date
Alkyl substituted
USA, UK, France, Spain, Germany, Sweden, India, China, Mexico, JapanGranted2025 EU/row
2028 USA
New medical useUSA, EUNational Phase2041
Rabeximod in treatment in RA USA, EU, China, Japan, South Korea, Australia, CanadaNational Phase2041
New oral formulation USA, EU, China, Japan, South Korea, Australia, CanadaNational Phase2041
Large scale process USA, EU, China, Japan, South Korea, Australia, Canada, IndiaNational Phase2041
Salt forms of rabeximodUSAGranted2042


Patent nameGeographiesSatusExpiration date
Cyclotides as immunosuppressive agents*USA, Europe, Canada, AustraliaGranted2032 EU/row/USA + PE
Cyclotides in combination with kappa opioid receptor ligands for MS therapy*Canada, China, EU, Japan, South Korea, USANational Phase2041

* Patent is co-owned by the Medical University of Vienna and the University of Freiburg, with Cyxone AB holding an exclusive fully paid-up license